My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Pluristem Therapeutics (PSTI)
NASDAQ:PSTI
PSTI nasdaq
United States
Pluristem

Pluristem Stock Analysis & Ratings

Pluristem Stock Analysis Overview

Smart Score
1
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Pluristem stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

PSTI

PSTI Stock Stats

Previous Close$2.47
Open$0
Bid2.45 x 200
Ask2.52 x 99
Today’s Range$0 - $0
52-Week Range$2.44 - $11.85
Volume1.11K
Average Volume213.85K
Market Cap$79.05M
Beta2.30
P/E Ratio-1.5
EPS-1.76
Earnings DateNov 08, 2018

Company Description

Pluristem Therapeutics

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Sector
Healthcare
Industry
Biotechnology
CEO
Yaky Yanay
Employees
162
ISIN
US72940R3003
Address
MATAM Advanced Technology Park, Haifa, 3508409, IL

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

PSTI FAQ

What was Pluristem’s price range in the past 12 months?
Pluristem lowest stock price was $2.44 and its highest was $11.85 in the past 12 months.
    What is Pluristem’s market cap?
    Pluristem’s market cap is $79.05M.
      What is Pluristem’s price target?
      Currently, no data Available
      What do analysts say about Pluristem?
      Not enough analysts have published a price target to provide an average price target.
      When is Pluristem’s upcoming earnings report date?
      Pluristem’s upcoming earnings report date is Nov 08, 2018 which is 3 years ago.
        How were Pluristem’s earnings last quarter?
        Pluristem released its earnings results on May 10, 2018. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $0.8.
          Is Pluristem overvalued?
          According to Wall Street analysts Pluristem’s price is currently Overvalued.
            Does Pluristem pay dividends?
            Pluristem does not currently pay dividends.
            What is Pluristem’s EPS estimate?
            Pluristem’s EPS estimate is -$0.77.
              How many shares outstanding does Pluristem have?
              Pluristem has 32,000,000 shares outstanding.
                What happened to Pluristem’s price movement after its last earnings report?
                Pluristem reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went up 0.847%.
                  Which hedge fund is a major shareholder of Pluristem?
                  Among the largest hedge funds holding Pluristem’s share is ARK Investment Management LLC. It holds Pluristem’s shares valued at 5M.

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis